Allopurinol in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

• The investigators evaluated the role of allopurinol in prevention of post-ERCP pancreatitis.

• 100 Egyptian patients who were candidates for ERCP were included and divided into two groups. Group 1 (study group) included 50 patients who received two doses of allopurinol 300 mg each, 15 hours and 3 hours before ERCP and Group 2 (control group) included 50 patients who did not receive allopurinol prophylaxis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Allopurinol

Criteria

Inclusion Criteria:

• Patients who were going to be subjected to ERCP due to different causes

Exclusion Criteria:

• Patients with clinically evident acute pancreatitis or hyperamylesemia (≥150 IU/L) before the procedure.

• Current or recent use of allopurinol (within the last 48 hours).

• Hypersensitivity to allopurinol or hydro-soluble contrast solutions.

• Current use of drugs with a known interaction with allopurinol, including cyclophosphamide, chlorpropamide, azathioprine, mercaptopurines, or probenecid.

• NSAIDS intake within a week prior to assessment.

• Previous endoscopic or surgical sphincterotomy.

• Those with severe co-morbid conditions.

• Female patients with a known or suspected pregnancy and/or lactation.